Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 7/20 | 0.36 |
| ▸ | GYS1 | P13807 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762471 | 0.88 | HTR1A (0.39) | HTR1ADGAT1PARP1PARP10PARP15 | |
| SCHEMBL5763798 | 0.86 | GYS1 (0.35) | HTR1AGYS1CES2CES1 | |
| SCHEMBL5567144 | 0.81 | ABL1 (0.35) | GYS1CES2CES1SLC6A4 | |
| SCHEMBL6436506 | 0.78 | GYS1 (0.33) | GYS1 | |
| SCHEMBL1362915 | 0.77 | CA1 (0.34) | GYS1 | |
| SCHEMBL5760894 | 0.76 | ALB (0.33) | GYS1CES2CES1 | |
| SCHEMBL1477045 | 0.72 | RXFP1 (0.35) | — | |
| SCHEMBL5760523 | 0.71 | PARP1 (0.42) | PARP1 | |
| SCHEMBL5565931 | 0.70 | HTR1A (0.38) | HTR1ADGAT1PARP1 | |
| SCHEMBL5322267 | 0.68 | PARP1 (0.50) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4705307-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-7265251-B2 | Process for the preparation of nitroalkenes | ZAMBON GROUP S.P.A. (IT) | 2007-09-04 | — | — | US | claimed |
| US-20060063953-A1 | Process for the preparation of nitroalkenes | ZAMBON GROUP S.P.A (IT) | 2006-03-23 | — | — | US | claimed |
| CN-1232480-C | Process for the preparation of nitroalkenes | ZAMBON SPA (IT) | 2005-12-21 | — | — | CN | claimed |
| EP-1294658-B1 | PROCESS FOR THE PREPARATION OF NITROALKENES | ZAMBON SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2004501878-A | — | — | 2004-01-22 | — | — | JP | claimed |
| US-20040006248-A1 | Process for the preparation of nitroalkenes | ZAMBON GROUP S.P.A (IT) | 2004-01-08 | — | — | US | claimed |
| CN-1438977-A | Process for the preparation of nitroalkenes | ZAMBON SPA (IT) | 2003-08-27 | — | — | CN | claimed |
| EP-1294658-A1 | PROCESS FOR THE PREPARATION OF NITROALKENES | ZAMBON GROUP S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000575-A1 | PROCESS FOR THE PREPARATION OF NITROALKENES | ZAMBON GROUP S.P.A. (IT) | 2002-01-03 | — | — | WO | claimed |
| US-7265251-B2 | Process for the preparation of nitroalkenes | ZAMBON GROUP S.P.A. (IT) | 2007-09-04 | — | — | US | disclosed |
| CN-1860112-A | 3-amino chroman and 2-amino tetralin derivatives | WYETH CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060063953-A1 | Process for the preparation of nitroalkenes | ZAMBON GROUP S.P.A (IT) | 2006-03-23 | — | — | US | disclosed |
| CN-1232480-C | Process for the preparation of nitroalkenes | ZAMBON SPA (IT) | 2005-12-21 | — | — | CN | disclosed |
| EP-0975618-B1 | a new process for the preparation of 3-N,N-dicycobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | EP | disclosed |
| US-6197978-B1 | ESTERIFICATION, PROPARYLATION, HEATING, HYDROLYSIS, ETHERIFICATION, REDUCTION, ALKYLATION, CYCLIZATION, AMINATION | ASTRA AKTIEBOLAG (SE) | 2001-03-06 | — | — | US | disclosed |
| CN-1259941-A | new method | ASTRA AB (SE) | 2000-07-12 | — | — | CN | disclosed |
| EP-0975618-A1 | A NEW PROCESS | Astra Aktiebolag (SE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046586-A1 | A NEW PROCESS | ASTRA AKTIEBOLAG (SE) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006248-A1 | Process for the preparation of nitroalkenes | NOS1, NOS2, NOS3 | HTR1A 1174/4885DGAT1 1469/4885PARP1 1956/4885 |
| US-20060063953-A1 | Process for the preparation of nitroalkenes | NOS2, NOS1, CBR1 | HTR1A 1534/4885DGAT1 1921/4885PARP1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.